news
Novel pseudo-virion probes to study SARS-CoV-2 viral entry
The non-infectious quantum dot probes are designed to enable researchers to safely study interactions between the SARS-CoV-2 Spike (S) protein and human cells.
List view / Grid view
Proteomics
news
Mystery glycoprotein could prevent respiratory distress
According to researchers, the DMBT1S8 molecule can halt inflammation in the respiratory tract through its interaction with the Siglec-8 receptor on immune cells.
news
A novel drug target for viral encephalitis therapies
Researchers showed CXCL1 signalling to neutrophils drove brain inflammation in herpes simplex virus (HSV) encephalitis and blocking the protein resulted in less severe disease.
news
Drug target to combat three coronavirus diseases identified by researchers
Researchers studying the PLpro binding site of three coronaviruses, including SARS-CoV-2, say the BL2 loop could be targeted by antiviral drugs.
article
Exploring the intra-protein non-covalent interactions in the S1 domain of the SARS-CoV-2 S1 Spike protein
The Spike (S) protein is a promising drug target in the quest to develop vaccines and antivirals for SARS-CoV-2 to treat and prevent COVID-19. Intra-protein interaction energy landscape mapping efforts have recently identified key interactions that may be crucial for the S protein’s ability to bind to receptor proteins on…
article
Novel biomarker technology for cancer diagnostics
A new way of identifying cancer biomarkers has been developed by researchers at Lund University in Sweden. The new technology allows very sensitive, quick and cost-effective identification of cancer biomarkers. Nikki Withers spoke to Professor Carl Borrebaeck, who discusses how the researchers demonstrated the power of combining proteomics with genomics.
article
Bispecific antibodies: the next generation of immuno-oncology drugs
Taylor B Guo, Chief Scientific Officer at I-Mab, describes the potential benefits of bispecific antibodies for cancer therapy and how their dual targeting mechanisms of action may drive their emergence as the next generation of immuno-oncology drugs.
article
Antibody therapeutics for COVID-19
In 2019, the SARS-CoV-2 coronavirus sparked a global pandemic that is likely to continue into 2021. Effective therapeutics that treat the symptoms of the disease and prevent or treat the underlying viral infection are critically required. To meet this need, the global biopharmaceutical industry is evaluating over 50 monoclonal antibody…
article
SARS-CoV-2, a spillover from animals to man, a spillback from man to animals and… what next?
Professor Giovanni Di Guardo discusses the relationship between animals and humans in regards to the transmission of SARS-CoV-2.
article
Assays In-Depth Focus 2020
In this In-Depth Focus find articles exploring the roles of key proteins implicated in Alzheimer's disease and a new technology enabling the identification of novel cancer biomarkers.
article
Targets In-Depth Focus 2020
This in-depth focus includes articles on the importance of a novel target to treat M. tuberculosis infections and how recently identified interactions between the SARS-CoV-2 Spike protein and host epithelial cells could be used in the development of COVID-19 therapeutics.
news
Genetic analysis reveals disease-causing protein drug targets
An analysis of blood protein levels has supported drug target prioritisation by identifying the causal effects of proteins on diseases, a team has shown.
article
Drug Target Review – Issue 3 2020
This issue includes articles that explore how a next-generation genomics platform can be used for COVID-19 research, the elimination of neutralising AAV antibodies for gene therapies and a new quick and cost-effective biomarker technology for cancer diagnostics. Also in this issue are features on antibody therapeutics for COVID-19 and targets…
news
Astrocytes likely contribute to Parkinson’s disease progression
A new study shows astrocytes derived from monogenic Parkinson’s patients have metabolic alterations that mean they could be contributing to disease progression.
article
Innovations for next-generation antibody-drug conjugates
Dr Amrik Basran and Dr Matt Vincent discuss various developments for antibody-drug conjugates to treat cancer.